MiMedx Group, Inc. (MDXG) Report Analysis
Corporate Events
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 3000 Growth Index
2022-06-24 00:00:00
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 3000 Growth Index
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 2000 Growth Index
2022-06-24 00:00:00
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 2000 Growth Index
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell Small Cap Comp Growth Index
2022-06-24 00:00:00
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell Small Cap Comp Growth Index
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 3000E Growth Index
2022-06-24 00:00:00
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 3000E Growth Index
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell Microcap Growth Index
2022-06-24 00:00:00
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell Microcap Growth Index
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 2500 Growth Index
2022-06-24 00:00:00
MiMedx Group, Inc.(NasdaqCM:MDXG) dropped from Russell 2500 Growth Index
MiMedx Group, Inc. has filed a Shelf Registration in the amount of $9.72 million.
2022-06-17 00:00:00
MiMedx Group, Inc. has filed a Shelf Registration in the amount of $9.72 million. Security Name: Common Stock Securities Offered: 3,000,000 Transaction Features: ESOP Related Offering
MIMEDX Engages Nordic Bioscience Clinical Development A/S to Propel Registrational Trials of Placental Biologic Injectable for Knee Osteoarthritis
2022-06-15 12:30:00
MiMedx Group, Inc. announced a collaboration agreement with Nordic Bioscience Clinical Development A/S. Image Analysis Group will also provide advanced tools to detect the potential for the Company’s placental biologic injectable, micronized dehydrated Human Amnion Chorion Membrane (mdHACM), to act as a Disease Modifying Osteoarthritis Drug (DMOAD) and potentially moderate the progression of OA. The Company plans to initiate its registrational Knee Osteoarthritis (KOA) clinical trial program later this year, using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain and WOMAC Function as co-primary endpoints. As MIMEDX’s selected CRO, NBCD will provide full operational support for the upcoming KOA clinical trial program, helping identify and select clinical trial sites and manage patient recruitment and enrollment. In addition, they will oversee clinical trial site monitoring, data management, and statistical analysis and reporting activities. Image Analysis Group will partner with MIMEDX and NBCD to incorporate imaging techniques and analytic approaches the Company plans to utilize in its KOA clinical trial program.
Declaration of Voting Results by MiMedx Group, Inc
2022-06-13 17:26:00
On June 13, 2022, MiMedx Group, Inc announced that at its annual general meeting of shareholders held on June 7, 2022, the shareholders of the Company: (1) elected James L. Bierman and Phyllis I. Gardner as directors; (2) approved an advisory resolution regarding executive compensation.
MiMedx Group Provides Information to Shareholders
2022-06-07 21:05:00
On June 7, 2022, MiMedx Group, Inc. announced that, based on the preliminary vote count provided by its proxy solicitor, shareholders have approved all proposals set forth by the Company at the 2022 annual meeting of shareholders, including the reelection of both of the Company’s directors, Phyllis Gardner and James L. Bierman, and the proposals on say-on-pay and the Company’s qualified employee stock purchase plan. The Company stated that it expects to file the final voting results, as tabulated by the independent Inspector of Elections, in a Form 8-K with the Securities and Exchange Commission.
MIMEDX Reminds Shareholders to Pre-Register for the Upcoming Virtual Annual Shareholders Meeting
2022-06-03 17:01:00
On June 3, 2022, MiMedx Group, Inc. published a press release reminding shareholders to pre-register for the upcoming 2022 annual meeting of shareholders, by no later than June 6, 2022.
MIMEDX Group Addresses Presentation by Prescience Point
2022-06-03 14:00:00
On June 3, 2022, MiMedx Group, Inc. announced that it has addressed a presentation published by Prescience Point on May 31, 2022, which mischaracterizes facts and relies on outdated and irrelevant information. The Company stated that it has regularly communicated factual, transparent and robust updates to shareholders around the decisive actions taken to successfully sustain, stabilize and grow the Company over the past 3 years, including its clear strategy for long-term shareholder value creation. The Company added that it reminds shareholders to visit www.votemimedx.com for access to communications materials that have been issued in connection with the 2022 annual meeting of shareholders, including a comprehensive investor presentation, as well as shareholder letters and press releases, which are also available on www.mimedx.com.
MiMedx Group Solicits Proxies from Shareholders
2022-06-02 13:03:00
On June 2, 2022, MiMedx Group, Inc. announced that it has addressed the misleading presentation published by Prescience Point on May 31, 2022, which mischaracterizes important facts and relies on outdated and irrelevant information. Further, the Company added that it has regularly communicated factual, transparent and robust updates to shareholders around the decisive actions taken to successfully sustain, stabilize and grow the Company. Later, the Company stated that it has urged the shareholders to vote for its proxy card.
MIMEDX Group Writes Letter to Fellow Shareholders
2022-05-31 21:05:00
On May 31, 2022, MiMedx Group, Inc. mailed a letter to shareholders from Board Chair M. Kathleen Behrens in connection with its 2022 annual meeting of shareholders scheduled for June 7, 2022, which would be held in virtual format at www.cesonlineservices.com/mdxg22_vm. The Company’s Board of Directors recommends unanimously that shareholders vote the Company’s proxy card for both of its directors standing for election – James L. Bierman and Phyllis Gardner.
Prescience Point Capital Releases Presentation Detailing Board and Management Failures at MiMedx Group
2022-05-31 19:05:00
On May 31, 2022, Prescience Point Capital Management LLC released a presentation detailing the failures and value destruction that have taken place under MiMedx Group, Inc.'s current Board of Directors and management. Prescience Point Capital stated that the presentation also documents a misalignment of interests that has given an incentive to management, the Board and EW Healthcare Partners to keep the Company's share price depressed. Prescience Point Capital also stated that the presentation reinforces its decision to withhold its votes against 2 members of the Company's Board, Phyllis Gardner and James Bierman, who are up for election at the Company's annual meeting of shareholders on June 7, 2022, and to vote against approval of the executive compensation package.
MiMedx Receives $4.6 Million Award from the Department of Defense to Advance the Treatment of Combat Casualty Wounds and Burns
2022-05-31 12:00:00
MiMedx Group, Inc. announced receiving a $4.6 Million award to evaluate PURION(R) processed Dehydrated Human Amnion Chorion Membrane (DHACM) as an advanced treatment option for wound and burn care. The award from the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command, is sponsored and will be managed by the Naval Medical Research Center (NMRC) to advance medical treatments for combat wounds and burns. Advanced wound and burn treatment approaches that can be applied quickly and easily in military relevant environments are needed to provide better outcomes for U.S. Armed Forces personnel. According to a 2018 study published in the Journal of Burns, burn injuries accounted for almost 10% of all combat casualties suffered by frontline military personnel during Operations Enduring Freedom and Iraqi Freedom. Despite best medical efforts, the mortality rate is dramatically higher for the warfighters who cannot be evacuated quickly from the field to higher-level trauma facilities, as the management of thermal wounds and combat related burn casualties can be very challenging in the deployed environment.
Institutional Shareholder Services Supports MiMedx Group
2022-05-25 22:26:00
On May 25, 2022, MiMedx Group, Inc. announced that a proxy advisory firm Institutional Shareholder Services (ISS) has recommended that shareholders vote for all of the Company’s proposals including for both of the Company director nominees – James L. Bierman and Phyllis Gardner, on the Company’s proxy card at its 2022 annual meeting of shareholders scheduled for June 7, 2022, which would be held in virtual format at www.cesonlineservices.com/mdxg22_vm.
Glass Lewis & Co Supports MiMedx Group Inc Nominees and Proposals
2022-05-20 14:00:00
On May 20, 2022, MiMedx Group Inc announced that independent proxy advisory firm Glass Lewis & Co recommended its shareholders to vote for all its board nominees and Company’s Say-on-Pay Proposal at the annual meeting of shareholders scheduled to be held on June 7, 2022.
MiMedx Group Files an Investor Presentation to Shareholders
2022-05-18 21:18:00
On May 18, 2022, MiMedx Group, Inc. filed an investor presentation with the U.S. Securities and Exchange Commission in connection with its 2022 annual meeting of shareholders, which is scheduled to be held on June 7, 2022. The Company stated that the presentation, and other important shareholder materials, are available at www.VoteMIMEDX.com. The Company added that it urges shareholders to vote for its Director nominees – James L. Bierman and Phyllis Gardner – on the Company’s proxy card.
Prescience Point Capital Management Provides Information to the Shareholders
2022-05-18 13:55:00
On May 18, 2022, Prescience Point Capital Management LLC issued a statement expressed its sisappoint that the MiMedx Board has resorted to disinformation and distortions to distract shareholders from the board's and management's own failures. Prescience Point reiterates its intention to withhold votes against directors Phyllis Gardner and James Bierman at 2022 annual meeting and vote against approval of executive compensation.
MiMedx Group Inc Mails Letter to Shareholders
2022-05-16 13:00:00
On May 16, 2022, MiMedx Group Inc sent a letter to shareholders highlighting the Company strategies and plans in connection with the shareholders value creation. In addition, the Company urged the shareholders to vote for its board nominees at the annual meeting of shareholders scheduled to be held on June 7, 2022.
MIMEDX Group, Inc Comments on Prescience Point Capital Management Statements
2022-05-09 13:00:00
On May 9, 2022, MIMEDX Group Inc commented on Prescience Point Capital Management’s press release on May 6, 2022, and mentioned the role of current board in transforming the Company and creating value to the shareholders. In addition, the Company urged the shareholders to vote for its board nominees Phyllis Gardner and James L. Bierman at the annual meeting of shareholders to be held on June 7, 2022.
Prescience Point Capital Management LLC Provides Information to Shareholders of MiMedx Group, Inc
2022-05-09 09:53:00
On May 9, 2022, Prescience Point Capital Management LLC provided supporting statements to its proposals in connection with the 2022 annual meeting of shareholders. In addition, Prescience Point Capital Management LLC urged the shareholders of MiMedx Group, Inc to withhold vote to Company nominees to the board and vote against the Company proposal for advisory approval of executive compensation, at the annual meeting of shareholders to be held on June 7, 2022.
Prescience Point Capital Management LLC Issues Open Letter to Shareholders of MiMedx Group Inc
2022-05-06 14:12:00
On May 6, 2022, Prescience Point Capital Management LLC sent aletter to shareholders of MiMedx Group Inc and announced that it intends to withhold its votes against 2 members of Company's board of directors, Phyllis Gardner and James Bierman and vote against Company's proposal for advisory approval of executive compensation, at the annual meeting of shareholders scheduled to be held on June 7, 2022.
patientNOW, Inc, Rx Marketing Group, 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, May 11, 2022 through May 15, 2022
2022-05-05 12:30:00
patientNOW, Inc, Rx Marketing Group, 17th Edition of the Music City Symposium for Cosmetic Advances & Laser Education, May 11, 2022 through May 15, 2022. Venue: Nashville, Tennessee, United States.
MiMedx Group, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 10:00 AM
2022-05-05 12:00:00
MiMedx Group, Inc. Presents at H.C. Wainwright Global Investment Conference 2022, May-24-2022 10:00 AM. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
MiMedx Group, Inc. Provides Sales Guidance for the Year 2022
2022-05-03 20:31:00
MiMedx Group, Inc. provided sales guidance for the year 2022. The company maintained its outlook for 2022, as disclosed in its earnings release for the year ended December 31, 2021, including that it expects net sales of its continuing portfolio of Advanced Wound Care products, which were $240.0 million in 2021, to grow 11% to 14% in 2022.
Prescience Investment Discloses its Views on MiMedx Group
2022-04-28 13:23:00
On April 28, 2022, Prescience Investment Group LLC announced that it has engaged in discussions with the Board, and are continuing to engage in such discussions, regarding suggestions aimed at improving the governance and chronic underperformance of MiMedx Group, Inc., including the addition of shareholder representatives to the Board. Prescience Investment stated that while it remains hopeful that a cooperative solution can be reached with the Company regarding representation on the Board, Prescience Investment added that it reserves all of its rights to take whatever actions it believe might be necessary at the upcoming 2022 annual meeting of shareholders in order to hold members of the Board accountable for the destructive status quo, including a proxy campaign to prevent the re-election of Phyllis Gardner and James Bierman.
MiMedx Group, Inc., Annual General Meeting, Jun 07, 2022
2022-04-26 20:06:00
MiMedx Group, Inc., Annual General Meeting, Jun 07, 2022, at 09:00 US Eastern Standard Time. Agenda: The election of two directors named in the accompanying proxy statement; to consider the advisory approval of the Company’s executive compensation; to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022; to approve adoption of an Employee Stock Purchase Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournment or any postponement thereof.
MiMedx Group, Inc. - Shareholder/Analyst Call
2022-04-26 20:06:00
Annual meeting of shareholders
MiMedx Group, Inc., Q1 2022 Earnings Call, May 04, 2022
2022-04-20 12:00:00
MiMedx Group, Inc., Q1 2022 Earnings Call, May 04, 2022
MiMedx Group, Inc. to Report Q1, 2022 Results on May 03, 2022
2022-04-20 12:00:00
MiMedx Group, Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022
MiMedx Group, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 12:15 PM
2022-03-22 05:03:00
MiMedx Group, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 12:15 PM. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States. Speakers: Peter Martin Carlson, Chief Financial Officer, Timothy R. Wright, CEO & Director.
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022
2022-02-28 18:21:00
H.C. Wainwright & Co., LLC, H.C. Wainwright Global Investment Conference 2022, May 23, 2022 through May 26, 2022. Venue: Fontainebleau Miami Beach Hotel, 4441 Collins Avenue, Miami Beach, Florida, United States.
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022
2022-02-17 10:42:00
Bank of America Corporation, Bank of America 2022 Healthcare Conference, May 10, 2022 through May 13, 2022. Venue: Encore Hotel, 3121 Las Vegas Blvd. S, Las Vegas, Nevada, United States.
Mimedx Group, Inc. to Provide New Details About Near- and Long-Term Growth Opportunities for Its Multimodal Placental Tissue Platform
2021-12-07 12:00:00
MiMedx Group, Inc. will provide new details about near- and long-term growth opportunities for its multimodal placental tissue platform at virtual Investor Day on December 7, 2021, which begins at 9:00 a.m. ET. The Investor Day will provide updates by Company leadership, third-party experts and key opinion leaders on the musculoskeletal late-stage pipeline and robust commercial business. Key Insights to Be Shared at MIMEDX 2021 Investor Day Include: Additional analyses from and next steps for the KOA clinical program: Third-party biostatisticians validated the statistically significant and clinically meaningful improvement in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain at three and six months, respectively (p=0.032 and p=0.009), WOMAC Function (p=0.046 and p=0.009), and WOMAC Total (p=0.038 and p=0.008) for the Pre-Interim Analysis Cohort of 190 patients. Root-cause analysis has determined that the potency of the investigational product faded as it aged, which resulted in the study’s failure to meet its primary endpoints. An intense examination of study results identified this factor as the primary difference in clinical responses observed between the Pre-Interim Analysis Cohort of 190 patients and the Post-Interim Analysis Cohort of 256 patients. MIMEDX proprietary biochemical and biological tests detected this reduced potency, related to age of the investigational product used in the Phase 2B KOA study. The Company is confident in its manufacturing processes and proprietary tissue engineering know-how and has a clear path forward. Based on the clinically meaningful and statistically significant data from the Pre-Interim Analysis Cohort of 190 patients in the Phase 2B trial, published retrospective data, extensive real-world clinical use, and ongoing scientific mechanism of action research, the Company believes that future planned KOA trials have an increased probability of success, benefitted by the learnings gained from the exploratory Phase 2B KOA clinical trial. Commencing in 2022, MIMEDX expects to initiate Phase 3 trials for its KOA candidate, with a Biologics License Application (BLA) filing anticipated in late 2025, and will work closely with the U.S. Food & Drug Administration (FDA) in advancing these trials. Robust Commercial Growth Potential: MIMEDX anticipates achieving sustainable growth of 11-14% across its vibrant commercial portfolio. This above-market growth rate comprises: An increase in its Advanced Wound Care business, driven by broadened product access across multiple underpenetrated markets, along with commercial excellence initiatives. An increase in its Surgical Recovery business, driven by market development, product innovation and increased clinical and economic evidence. An increase in its international markets, driven in part by its Japanese commercial strategy. The Company also has a robust near-term product pipeline, with two new product launches anticipated in the first half of 2022.
MiMedx Group, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021
2021-11-22 15:06:00
MiMedx Group, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States. Speakers: Rohit Kashyap, Executive VP & Chief Commercial Officer, Timothy R. Wright, CEO & Director.
MiMedx Group, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM
2021-11-22 13:00:00
MiMedx Group, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.
Mimedx Group, Inc. Announces Publication of Peer-Reviewed Study in Facial Plastic Surgery & Aesthetic Medicine Investigating the Safety and Utility of PURION Processed dHACM for Use in Mohs Micrographic Surgeries
2021-11-17 13:00:00
MiMedx Group, Inc. announced publication of a peer-reviewed study in Facial Plastic Surgery & Aesthetic Medicine investigating the safety and utility of the Company’s PURION processed dHACM for use in Mohs micrographic surgeries. The retrospective propensity score-matched case-control study demonstrated that PURION processed dHACM placental allografts were associated with a statistically significant lower risk for infection, poor scar cosmesis, scar revision, and additional operation at the index site, when compared to traditional methods of incisional repair. The findings indicate that placental allografts may be a viable alternative to autologous tissue-based reconstruction, including flaps and full-thickness skin grafts (FTSG), particularly in an aging population undergoing numerous Mohs procedures in moderate to high-risk areas of the face, head, neck, and dorsal hand. Mohs micrographic surgery is considered the most effective technique for treating many basal and squamous cell carcinomas, the two most common types of non-melanoma skin cancer. With the incidence of NMSC increasing rapidly in people over 65, Mohs has become a common procedure to remove these cutaneous malignancies. In some cases, lesions occur multiple times in a localized region and repeat surgery to remove them impacts quality and availability of nearby autologous tissue, thereby impacting the aesthetic and functional success of graft or flap procedures. To complicate matters, tumors among the elderly are often more invasive, and obtaining cancer-free margins can result in significant tissue loss, which further increases the need to consider alternative tissue sources. The retrospective, case-controlled study patient population included 143 propensity score-matched pairs undergoing MMS for a basal or squamous cell carcinoma on the face, head, neck, or dorsal hands with same-day reconstruction using either autologous tissue or dHACM placental allograft, between January 2014 and December 2018. The size, location, and reconstructive complexity of defects repaired by both approaches were equivalent. The study compared a variety of post-surgical medical complications, such as infection, bleeding, dehiscence, additional operation and development of a non-healing wound, as well as cosmetic outcome measures, including suboptimal scarring and scar revision or treatment. Patients who received placental allografts were 12 times less likely to have a post-surgical infection or require additional surgery, and 19 times less likely to have unacceptable scarring. A significantly greater proportion of patients in the placental allograft group (97.9%) experienced zero postoperative complications compared to patients undergoing autologous tissue-based repairs. Placental allograft cases developed less infection than their flap and FTSG counterparts, and no instances of bleeding, dehiscence, non-healing wounds, scar revision, additional operation at the index site, or poor scar cosmesis were observed. These findings support the potential for use of the Company’s PURION processed dHACM placental allografts as an alternative to existing methods for reconstructive repair in Mohs procedures, particularly in older patients with moderate to high-risk defects.
MiMedx Group, Inc. Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 09:30 AM
2021-11-02 12:00:00
MiMedx Group, Inc. Presents at 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov-18-2021 09:30 AM. Speakers: Peter Martin Carlson, Chief Financial Officer, Rohit Kashyap, Executive VP & Chief Commercial Officer, Timothy R. Wright, CEO & Director.
MiMedx Group, Inc. Announces Two Peer Reviewed Studies Investigating the Use of Micronized Dehydrated Human Amnion Chorion Membrane
2021-11-01 12:30:00
MiMedx Group, Inc. announced two peer-reviewed studies investigating the use of micronized dehydrated human amnion chorion membrane (mdHACM) for the treatment of debilitating conditions involving degeneration of connective tissue: osteoarthritis (OA) and tendinopathy. The first study, published in Osteoarthritis and Cartilage Open, identified a novel mechanism of action by which PURION® Processed mdHACM regulates degradative processes in human articular chondrocytes, the primary cell type comprising articular cartilage. These results further support mdHACM as an investigational new drug (IND) candidate for the treatment of OA and highlight potential disease modifying activities. The second study, published in the Journal of Biomedical Materials Research, Part B, examined chronicity and poor outcomes following tendon injury attributable to prolonged inflammation and hypervascularity. These complications were modeled in vitro for the purposes of evaluating mdHACM as a treatment for tendinopathy, which led to the identification of specific mechanisms responsible for counteracting these disease processes. With more than 300 million global cases of hip and knee OA and the current treatment paradigm focusing primarily on symptomatic relief (Non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid injections) followed by prosthetic joint replacement when needed, developing a regenerative therapy that addresses the underlying structural damage is becoming increasingly more important. Micronized dHACM is hypothesized to target specific OA-related pathways to re-establish homeostasis, and thereby mitigate the physical effects of OA. To test this theory, an in vitro system was developed to recapitulate the disease state. OA was modeled using an established in vitro platform consisting of a 3D pellet culture of human articular chondrocytes and a cartilaginous extracellular matrix (ECM). The addition of inflammatory stimuli induced OA-like changes and elevated two key signaling pathways associated with disease progression, NF-?ß (Nuclear Factor kappa-light-chain-enhancer of activated B cells) and canonical Wnt signaling. Introduction of mdHACM treatment specifically inhibited these pathways (Figure 1), effectively reversing the effects of the inflammatory stimuli and diminishing the expression and activity of key enzymes responsible for cartilage matrix degradation. While the onset of OA is likely multifactorial, this study indicates mdHACM regulation of both NF-?ß and canonical Wnt signaling is one such mechanism by which this treatment elicits a chondroprotective effect and attenuates degeneration in vitro. This study substantiates previous clinical and preclinical evidence suggesting mdHACM treatment improves the outcomes associated with OA.
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021
2021-10-25 10:00:00
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.
MiMedx Group, Inc., Q3 2021 Earnings Call, Nov 03, 2021
2021-10-20 12:00:00
MiMedx Group, Inc., Q3 2021 Earnings Call, Nov 03, 2021
MiMedx Group, Inc. to Report Q3, 2021 Results on Nov 02, 2021
2021-10-20 12:00:00
MiMedx Group, Inc. announced that they will report Q3, 2021 results After-Market on Nov 02, 2021
Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021
2021-10-14 22:02:00
Canaccord Genuity LLC, 15th Annual Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, Nov 18, 2021.
MiMedx Group, Inc. - Analyst/Investor Day
2021-10-14 20:05:00
To discuss Company’s musculoskeletal late-stage pipeline and advanced wound care business
Net Health Announces Agreement with MiMedx Group, Inc
2021-10-13 11:00:00
Net Health announced that it has added MiMedx Group, Inc. to the list of leading wound care providers that rely on Net Health Wound Care's in-chart ordering platform, CTP Connections. Through the agreement, hospital and outpatient wound care providers can quickly and efficiently submit electronic insurance verification forms and secure approvals for MIMEDX tissue-based products.
MiMedx Group, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 03:30 PM
2021-10-01 10:34:00
MiMedx Group, Inc. Presents at 30th Annual Credit Suisse Healthcare Conference, Nov-09-2021 03:30 PM. Venue: Rancho Palos Verdes, California, United States. Speakers: Peter Martin Carlson, Chief Financial Officer, Rohit Kashyap, Executive VP & Chief Commercial Officer, Timothy R. Wright, CEO & Director.
Mimedx Reports Top-Line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology
2021-09-13 10:30:00
MiMedx Group, Inc. announced top-line results from two late-stage musculoskeletal clinical trials of the company’s micronized dehydrated Human Amnion Chorion Membrane (mdHACM): a Phase 2B clinical trial for the treatment of Knee Osteoarthritis (KOA) and a Phase 3 clinical trial for the treatment of Plantar Fasciitis (PF). Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B clinical trial for KOA did not meet primary endpoints, but did reveal varied efficacy signals between patient cohorts evaluated pre- and post- a blinded interim analysis performed in mid-2019, prompting the Company to plan for confirmatory efficacy studies for the KOA indication. The Phase 3 PF study did not meet its primary endpoint, and the company will not pursue a BLA for this indication at this time. Throughout both studies, the mdHACM product was found safe and well-tolerated. The Phase 2B KOA trial formally ends in October 2021. An interim review of the 446 patients enrolled in the clinical trial showed that the study did not meet its two primary efficacy endpoints of a statistically significant change in the Visual Analog Scale (VAS) for Pain or in the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. The top-line data indicate a potential positive clinical efficacy signal, but did not indicate a statistical difference between patients in the product treatment group and the placebo group, with all scores improving for both groups. Significant differences were observed between patients enrolled prior to the study’s initial blinded interim analysis (the Pre-Interim Analysis Cohort), and those patients enrolled following the initial blinded interim analysis (the Post-Interim Analysis Cohort). Patients in the treatment group in the Pre-Interim Analysis Cohort demonstrated a greater improvement in WOMAC-Total, WOMAC-Pain and WOMAC-Function scores, with statistically significant separation between treatment and placebo-treated patients at both the three-month and six-month endpoints. The patients in the Post-Interim Analysis Cohort showed a positive response to both treatment and placebo. Additional analyses are planned to explore these differences. Results for VAS did not indicate statistically significant differences between treatment and placebo-treated patients, or between the Pre-Interim Analysis Cohort and the Post-Interim Analysis Cohort at either the three-month or six-month endpoint, with a strong improvement in VAS observed across both cohorts. The company plans to meet with the FDA to thoroughly review the findings and determine the appropriate path forward toward the initiation of Phase 3 clinical trials in KOA. Based on the current analysis of the interim results for the Phase 2B clinical trial, the company now believes that two Phase 3 studies in KOA will be required to file a BLA and intends to provide an update for the timing of the filing, previously tentatively planned for late-2024 or early-2025, following review and discussion with the FDA. The Phase 3 PF study did not meet its primary endpoints. The product and placebo groups both improved during the treatment period, and demonstrated reduced VAS Pain and improved Foot Function Index-Revised (FFI-R) scores, without statistically significant separation between treatment groups. The company plans on a complete review of the full study data, but does not intend to pursue a BLA filing for PF at this time, instead focusing resources on advancing confirmatory Phase 3 studies for KOA. Both the Phase 2B KOA clinical trial and the Phase 3 PF clinical trial demonstrate strong safety results with no significant Adverse Events or Serious Adverse Events. The Company plans to review the full study results from both trials with investors at a future R&D Day, planned for later this year. Intra-articular Micronized dHACM Versus Saline in the Treatment of Osteoarthritis of the KneeTrial This study was a Phase 2B prospective, double-blinded, randomized controlled trial of PURION® Processed micronized dehydrated Human Amnion/Chorion Membrane (mdHACM) Injection, as compared to saline placebo injection in the treatment of osteoarthritis of the knee. Trial enrollment included 466 patients between the ages of 21 to 80 years, with a diagnosis of osteoarthritis defined as grade 1 to 3 on the Kellgren Lawrence grading scale and a Visual Analog Scale (VAS) for Pain score greater than 45. Due to a lower-than-expected number of study participant dropouts (3% in both arms) and with an adequate number of patients meeting the required time in study to assess the primary endpoint, the final number randomized was 446 patients. Micronized dHACM Injectable for the Treatment of Plantar Fasciitis TrialThis study was a Phase 3 prospective, double-blinded, randomized controlled trial of a single injection of 40 mg of PURION® Processed micronized dehydrated Human Amnion/Chorion Membrane (mdHACM) into the plantar fascia, as compared to saline placebo injection in the treatment of plantar fasciitis. The trial enrolled 277 patients between the ages of 21 and 79 years, with an investigator-confirmed diagnosis of plantar fasciitis for greater than or equal to one month (30 days) and less than or equal to 18 months. Patients were required to have a Visual Analog Scale (VAS) Pain score of greater than or equal to 45 mm at randomization and to have received conservative treatment for greater than or equal to 1 month (30 days), including any of the following modalities: Rest, Ice, Compression, Elevation (RICE); stretching exercises; NSAIDs; or orthotics. The primary endpoints were change in VAS for Pain at 90 days and incidence of related adverse events at 180 days, serious adverse events and unanticipated events during the first 12 months post-injection. Secondary endpoints included self-reported responses to the Foot Function Index – Revised (FFI-R) at 90 days.
MiMedx Group, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM
2021-09-09 01:39:00
MiMedx Group, Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 07:00 AM. Venue: Lotte New York Palace Hotel, New York City, New York, United States. Speakers: Peter Martin Carlson, Chief Financial Officer, Robert Benjamin Stein, Executive Vice President of Research & Development, Timothy R. Wright, CEO & Director.
MiMedx Group, Inc. has filed a Shelf Registration in the amount of $350 million.
2021-08-27 00:00:00
MiMedx Group, Inc. has filed a Shelf Registration in the amount of $350 million. Security Name: Common Stock Security Name: Preferred Stock Security Name: Debt Securities Security Name: Warrants Security Name: Units Transaction Features: Omnibus/Universal Shelf Registration
MIMEDX Promotes Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs
2021-08-12 12:30:00
MiMedx Group, Inc. announced the promotion of Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs. As a member of the Senior Leadership Team, Ms. Snyder will oversee strategic projects requiring cross-functional input, and drive the integration, effectiveness, and efficiency of decision making throughout the organization to advance multiple, company-wide initiatives. She will continue in her role as co-chair of the Company’s Inclusion and Diversity Council and serve as an important voice for MIMEDX’s government affairs and patient advocacy efforts. As a policy contributor and trusted advisor, she will serve as a significant communications link with the broader organization as a whole. With this promotion, the Company has commenced an executive search to fill Ms. Snyder’s prior role of Senior Vice President, Market Access. Ms. Snyder joined MIMEDX in 2013, and throughout her eight-year tenure she has continued to take on roles of increasing responsibility, most recently serving as Senior Vice President, Market Access. Prior to joining MIMEDX, Ms. Snyder spent 13 years with Pfizer in a variety of roles, including Director of Payer Marketing for Enbrel, and started her career in sales and sales management with Johnson & Johnson.
MiMedx Group, Inc. to Report Q2, 2021 Results on Aug 03, 2021
2021-07-20 12:00:00
MiMedx Group, Inc. announced that they will report Q2, 2021 results After-Market on Aug 03, 2021
MiMedx Group, Inc., Q2 2021 Earnings Call, Aug 04, 2021
2021-07-20 12:00:00
MiMedx Group, Inc., Q2 2021 Earnings Call, Aug 04, 2021
MiMedx Group, Inc. Presents at Stephens Annual Investment Conference, Nov-29-2021
2021-07-10 06:42:00
MiMedx Group, Inc. Presents at Stephens Annual Investment Conference, Nov-29-2021 . Venue: Omni Nashville Hotel, 250 Fifth Avenue South, Nashville, Tennessee, United States.
Fundamental Summary
MiMedx's financial reports for Q1 showed some underwhelming results. Specifically, their growth, value, and income factors indicate an execution challenge when it comes to generating exciting and consistent growth. These results suggest a challenging future for MiMedx's stock. As such, MiMedx received an overall score of 45 and a UNDERPERFORM recommendation.
MiMedx reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 58.89 million compared to USD 59.97 million a year ago. Net loss was USD 10.49 million compared to USD 8.38 million a year ago. Basic loss per share from continuing operations was USD 0.11 compared to USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.11 compared to USD 0.09 a year ago.
Business Description
MiMedx develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company’s products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx is headquartered in Marietta, Georgia.
Sector Overview
MiMedx is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. MiMedx's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | -14.7 | -31.1% | 83 | |
| Net Cashflow | -9.1 | -3.9% | 46 | |
| Capital Expenditure | -1.4 | 57.4% | 97 | |
| Asset Turnover | 1.4 | 6.3% | 86 | |
| Free Cashflow | -0.1 | -29.1% | 48 |
* All values are TTM
The below chart reflects MiMedx's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While MiMedx's peer average final assessment score stands on 71.0, MiMedx's score is 45.
- MDXG
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. MiMedx's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. The company is trading near it's 12-month low, which signals it struggle to keep above it support price. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), MiMedx's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 37.
5D MA
3.75
50D MA
3.78
200D MA
5.34
MACD
-0.04
RSI
13.24
STOCH
34.07
Balance Sheet Analysis
MiMedx's most recent balance sheet report was not encouraging. MiMedx publishes discouraging results related to book value factors in this report. As of the current filing, price to book ratio (P/B) was reported as -49.8, representing a -100.6% change from the previous report. This characteristic can affect companies in the same industry and market capitalization by up to 22.6%. They does not yet appear to be headed in the right direction to achieve strong book value metrics. Consequently, their book value factors movement received a grade of 37. Also, MiMedx published concerning equity metrics for this filing. In the current report, equity stood at -7.4, which represents a -9165.9% change from the last report. This parameter often affects companies in the same industry and market capitalization by up to 7.3%. These metrics are all the more disappointing relative to their peers and should blunt potential positive momentum in its's stock price. Its equity movement component, therefore, received a grade of 42. At the same time, one balance sheet metric, Assets, was actually strongly positive. MiMedx's management was effective in managing the value of the assets on their balance sheet, which now sits at 174.4 and represents a -7.2% change from the previous report. This growth should support upward pressure on its's stock price, which better captures their intrinsic value. The company's asset component, therefore, received a grade of 66. The company's balance sheet, Therefore, earned a score of 45.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 174.4 | -7.2% | 66 |
| Liabilities | 89.4 | -6.3% | 53 |
| Price to Book | -49.8 | -100.6% | 37 |
| Cash & Equivalents | 75.7 | -13.1% | 57 |
| Equity | -7.4 | -9165.9% | 42 |
The below chart describes MiMedx's performance as reflected on its balance sheet with respect to its peers. While MiMedx received a balance sheet score of 45, the average of its peers stands on 69.0.
- MDXG
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 2 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 7 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 8 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 9 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 10 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 16 | 1 |
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 20 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 21 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 22 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 24 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 33 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 35 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 37 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 41 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 43 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 45 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 51 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 59 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 63 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 65 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 74 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 79 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 46 | 68 | 57 | 41 | 61 | 57 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 87 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Results from MiMedx's current financials were concerning, in two areas in particular: EBITDA and Return Factors. MiMedx's management didn't make significant improvements to their EBITDA this period. In terms of the raw numbers, EBITDA was reported as -1.3, which represents a -184.5% change from the last period. This metric might have a 24.4 percent impact on companies in the same industry and with the same market capitalization. Their EBITDA metrics are even more problematic when compared to their peers. Therefore, their EBITDA component earned a score of 43. Also, In this filing, MiMedx reported a return on equity (ROE) ratio of -14.7, which represents a growth of -31.1%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. These numbers show that management has been unsuccessful in fostering appropriate growth related to return on assets and return on equity momentum relative to their peers. Consequently, their return factors received a grade of 83. That said, one metric, Revenue Efficiency, stood out as strongly positive. MiMedx did an excellent job managing its revenue efficiency this past period. MiMedx's revenue efficiency is 257.5 according to the metrics in the current filing, which represents a -0.4% change from the previous report. This parameter often affects companies in the same industry and market capitalization by up to 13.1%. Their revenue efficiency, specifically in contrast to their industry peers', should support a positive movement in the company's stock price. As a result, its revenue efficiency earned a score of 87. Because of these weaknesses, its income statement received an overall score of 59.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -1.3 | -184.5% | 43 |
| Total Revenues | 257.5 | -0.4% | 87 |
| Return on Equity | -14.7 | -31.1% | 83 |
The below chart describes MiMedx's performance as reflected on its income statement with respect to its peers. While MiMedx received a income statement score of 59 , the average of its peers stands on 71.0.
- MDXG
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 2 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 7 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 8 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 9 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 10 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 15 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 16 | 1 |
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 20 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 21 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 22 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 24 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 33 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 35 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 41 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 43 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 45 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 51 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 63 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 65 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 74 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 79 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 71 | 93 | 40 | 86 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 87 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 88 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Two main cash flow metrics, Capex and Asset Turnover, are driving the positive outlook for MiMedx's financial strength. MiMedx's management was effective in improving its CapEx, which now sits at -1.4 and represents 57.4% change from the previous report. This performance is all the more impressive relative to their peers and competitors. The company's CapEx movement, therefore, received a grade of 97. Also, MiMedx's published asset turnover numbers were encouraging and reflected management's balanced change strategy. MiMedx recorded asset turnover of 1.4, which represents a 6.3% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 4.1%. Their asset turnover numbers are significantly more impressive when contrasted against their peers and competitors. Therefore, its asset turnover movement earned a score of 86. However, one discouraging result, Net Cash Flow, stood out. MiMedx's net cash flow metrics were -9.1 according to their current filing, which represents a -3.9% change from the previous report. As demonstrated by these concerning net cash flow metrics, their priorities seem to be headed in the wrong direction. Its net cash flow, therefore, received a grade of 46. Their cash flow, therefore, earned a score of 60.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -9.1 | -3.9% | 46 |
| Capital Expenditure | -1.4 | 57.4% | 97 |
| Asset Turnover | 1.4 | 6.3% | 86 |
| Free Cashflow | -0.1 | -29.1% | 48 |
The below chart describes MiMedx's performance as reflected on its cash flow with respect to its peers. While MiMedx received a cash flow score of 60, the average of its peers stands on 73.0.
- MDXG
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 0 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 1 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 2 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 3 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 4 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 5 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 6 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 7 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 8 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 9 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 10 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 11 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 12 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 13 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 14 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 15 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 16 | 1 |
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 17 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 18 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 19 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 20 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 21 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 22 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 23 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 24 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 25 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 26 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 27 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 28 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 29 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 30 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 31 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 32 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 33 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 34 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 35 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 36 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 37 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 38 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 39 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 40 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 41 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 42 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 43 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 44 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 45 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 46 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 47 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 48 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 49 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 50 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 51 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 52 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 53 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 54 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 55 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 56 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 57 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 58 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 59 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 60 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 61 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 62 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 63 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 64 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 65 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 66 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 67 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 68 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 69 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 70 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 71 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 72 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 73 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 74 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 75 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 76 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 77 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 78 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 79 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 80 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 81 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 82 | 1 |
| Intercept Pharmaceuticals, Inc. | 386.3M | 87 | 95 | 98 | 89 | 96 | 83 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 84 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 85 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 86 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 87 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 88 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 89 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 90 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 91 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 92 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 93 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.